Analyst upgrades, especially from prominent firms like Goldman Sachs, can significantly influence investor sentiment and stock prices. The upgrade to 'Buy' and the setting of a $50 price target suggest a strong bullish outlook for CG Oncology, likely leading to increased investor interest and potentially higher stock prices in the short term.